Back to Browse Journals » Biologics: Targets and Therapy » Volume 2 » Issue 2

Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications

Authors Paul N Knoebl

Published 6 June 2008 Volume 2008:2(2) Pages 285—296


Paul N Knoebl

Department of Medicine 1, Division Hematology and Hemostasis, Medical University of Vienna, Vienna, Austria

Abstract: The protein C pathway has an important function in regulating and modulating blood coagulation and ensuring patency of the microcirculation. Protein C deficiency leads to macro- and microvascular thrombosis. Congenital severe protein C deficiency is a life-threatening state with neonatal purpura fulminans and pronounced coagulopathy. Patients with heterozygous protein C deficiency have an increased risk for thromboembolic events or experience coumarin-induced skin necrosis during initiation of coumarin therapy. Replacement with protein C concentrates is an established therapy of congenital protein C deficiency, resulting in rapid resolving of coagulopathy and thrombosis without reasonable side effects. This article summarizes the current knowledge on protein C replacement therapy in congenital protein C deficiency.

Keywords: protein C, deficiency, replacement therapy, purpura fulminans, coagulopathy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Disturbed spontaneous brain activity pattern in patients with primary angle-closure glaucoma using amplitude of low-frequency fluctuation: a fMRI study

Huang X, Zhong YL, Zeng XJ, Zhou F, Liu XH, Hu PH, Pei CG, Shao Y, Dai XJ

Neuropsychiatric Disease and Treatment 2015, 11:1877-1883

Published Date: 29 July 2015

Using registries to identify type 2 diabetes patients

Thomsen RW, Sørensen HT

Clinical Epidemiology 2015, 7:1-3

Published Date: 18 December 2014

Towards real-time detection of tumor margins using photothermal imaging of immune-targeted gold nanoparticles

Jakobsohn K, Motiei M, Sinvani M, Popovtzer R

International Journal of Nanomedicine 2012, 7:4707-4713

Published Date: 28 August 2012


De Caterina AR, Harper AR, Cuculi F

Vascular Health and Risk Management 2012, 8:443-445

Published Date: 19 July 2012

Etiology of hypercoagulable state in women with recurrent fetal loss without other causes of miscarriage from Southern Italy: new clinical target for antithrombotic therapy

Maristella D’Uva, Pierpaolo Di Micco, Ida Strina, Antonio Ranieri, Carlo Alviggi, et al

Biologics: Targets and Therapy 2008, 2:897-902

Published Date: 5 December 2008

Noxious counterirritation in patients with advanced osteoarthritis of the knee reduces MCC but not SII pain generators: A combined use of MEG and EEG

Markus Quante, Stephanie Hille, Markus D Schofer, Jürgen Lorenz, Michael Hauck

Journal of Pain Research 2008, 1:1-8

Published Date: 19 September 2008

Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases

Peter J O’Brien, Rajeev Ramanathan, Jonathan M Yingling, Jose Baselga, Mace L Rothenberg, et al

Biologics: Targets and Therapy 2008, 2:563-569

Published Date: 12 September 2008

The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT

Andreas Koster, Karl-Georg Fischer, Sebastian Harder, Fritz Mertzlufft

Biologics: Targets and Therapy 2007, 1:105-112

Published Date: 15 November 2007